Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Shares of Global Blood Therapeutics (GBT) are skyrocketing today, up by 36.6% as of 1:27 p.m. ET. The biotech's stock is roaring higher in the wake of a report from Bloomberg News that the company ...

SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of preliminary results from the single-dose ...

Global Blood Therapeutics revealed that there were around 925 new prescriptions for Oxbryta during Q2. In addition, the company revealed that they have seen a substantial number of patients that ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

So what Global Blood Therapeutics said it is selling 5.1 million shares of common stock to the public for $24.50 per share. That should net the company $125 million after deducting fees. The ...

What happenedShares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its ...

Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer will pay $68.50 a ...

Sickle cell disease is a genetic blood disorder that affects about 70,000 to 100,000 people in the U.S. Oxbryta generated $55.2 million in sales for Global Blood Therapeutics in the first quarter.

So what Global Blood Therapeutics has just one drug in its clinical-stage pipeline: voxelotor, an oral, once-daily treatment for sickle cell disease (SCD). Voxelotor helps prevent red blood cells ...

Shares of rare-disease specialist Global Blood Therapeutics (GBT) are rising sharply for the second day in a row. As of 12:38 p.m. ET, the drugmaker's stock was up by a healthy 38.4%.